Theseus Pharmaceuticals (THRX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Depreciation and amortization	10.46M
Stock-based compensation	6.42M
Forgiveness of notes receivable
Receivables
Prepaid expenses and other current assets	280K
Accounts payable	-290K
Accrued personnel-related expenses, accrued clinical and development expenses, accrued interest on convertible subordinated notes and other current liabilities	220K
Deferred rent
Deferred revenue	-664K
Other liabilities, non-current
Net cash used in operating activities	39.9M
Purchases of property and equipment	-250K
Purchases of marketable securities
Sales of marketable securities	3M
Maturities of marketable securities
Release of restricted cash
Additions to notes receivable
Payments received on notes receivable
Net cash used in investing activities	-27.9M
Payments on note payable and capital lease
Proceeds from issuances of common stock, net	341K
Net cash provided by financing activities	-77.98M
Net increase (decrease) in cash and cash equivalents	-65.99M
Cash and cash equivalents at beginning of period	159.18M
Cash and cash equivalents at end of period	93.19M

Entities mentioned with THRX

View All Entities